Scinai Immunotherapeutics Ltd. financial data

Symbol
SCNI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Jerusalem Biopark, 2 Nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel
State of incorporation
Israel
Fiscal year end
December 31
Former names
BiondVax Pharmaceuticals Ltd. (to 8/28/2023)
Latest financial report
Q4 2023 - May 15, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.86 B shares
Common Stock, Shares, Outstanding 1.86 B shares +87.7%
Entity Public Float 16.7 M USD
Weighted Average Number of Shares Outstanding, Basic 1.35 B shares +81%
Weighted Average Number of Shares Outstanding, Diluted 1.35 B shares +81%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.45 M USD -26.3%
General and Administrative Expense 1.14 M USD -11.5%
Operating Income (Loss) -2.6 M USD +20.5%
Nonoperating Income (Expense) -1.17 M USD -517%
Net Income (Loss) Attributable to Parent -3.76 M USD -26.1%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.87 M USD -65.4%
Other Assets, Current 437 K USD +182%
Assets, Current 5.45 M USD -62.1%
Property, Plant and Equipment, Net 10.8 M USD -3.74%
Operating Lease, Right-of-Use Asset 1.2 M USD -17.4%
Assets 17.5 M USD -35.4%
Employee-related Liabilities, Current 388 K USD -19.8%
Accrued Liabilities, Current 461 K USD -39%
Liabilities, Current 1.78 M USD -23.9%
Operating Lease, Liability, Noncurrent 797 K USD -26.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.74 M USD +13.3%
Retained Earnings (Accumulated Deficit) -122 M USD -5.61%
Stockholders' Equity Attributable to Parent -4.57 M USD -160%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -1.76 M USD -279%
Liabilities and Equity 17.5 M USD -35.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.06 M USD -177%
Net Cash Provided by (Used in) Investing Activities -6 K USD +98.8%
Common Stock, Shares Authorized 20 B shares 0%
Common Stock, Shares, Issued 1.86 B shares +87.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.29 M USD -65.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.01 M USD -64.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 725 K USD
Deferred Tax Assets, Valuation Allowance 26.4 M USD +18.2%
Operating Lease, Liability 420 K USD
Payments to Acquire Property, Plant, and Equipment 6 K USD -98.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3.61 M USD
Property, Plant and Equipment, Gross 13.6 M USD -0.24%
Operating Lease, Liability, Current 396 K USD +3.67%
Deferred Tax Assets, Operating Loss Carryforwards 26.1 M USD +20.4%
Additional Paid in Capital 120 M USD +2.95%
Depreciation, Depletion and Amortization 138 K USD +2.99%
Deferred Tax Assets, Net of Valuation Allowance 26.2 M USD +19%
Share-based Payment Arrangement, Expense 252 K USD -48%